RoboSense Market Share Ranks 1st in China, 2nd Worldwide: Yole 2021 Global LiDAR Industry Report
23.9.2021 15:30:00 EEST | Business Wire | Press release
RoboSense LiDAR, the leading Smart LiDAR Sensor provider, boasts 10 percent of the market share worldwide, ranking first in China and second globally, according to the “LiDAR for Automotive and Industrial Applications Report 2021” from Yole Développement, an international market research and strategic consultancy. The report covers the market share of automotive and industrial applications of over ten leading LiDAR companies worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005530/en/
LiDAR design wins*-RoboSense boasts 10% of the market share worldwide, ranking 1st in China and 2nd globally (Photo: Business Wire)
RoboSense has been designated as an official long-term partner for many auto companies, and receiving orders for its RS-LiDAR-M1 (M1), RoboSense’s second-generation solid-state LiDAR, for a diverse range of mass-produced models since July 2020. These orders cover traditional automobile manufacturers and a supercar brand. Among them, GAC-Aion officially announced its plans to equip multiple models with RoboSense LiDAR in July this year.
The report also noted that mechanical LiDAR systems, including rotary and rotating mirror systems, have been losing market share since 2020 due to cost and reliability issues. It goes on to state that second-generation MEMS Smart LiDAR systems are entering the mainstream as its technology matures and cost gets more competitive.
World's first mass-produced automotive-grade solid-state LiDAR
RoboSense’s M1 employs advanced MEMS technologies. Launched in 2016 and with a demo prototype on the way next year, M1 was first shown at the International Consumer Electronics Show (CES) in 2018 and won two CES Innovation Awards in 2019 and 2020.
With over five years of research and dozens of upgrades, M1 became the first product to have a mass-production version finalized. RoboSense began mass-produced automotive-grade production of M1 in Q2 2021, and has since delivered over ten batches for models through its long-term automobile manufacturer partnerships.
Exclusive smart “GAZE” functionalities
M1 boasts an exclusive smart functionality named “GAZE”, which dynamically improves resolution and frame rate based on the environment, enabling vehicles to zoom in and out and augmenting their perception.
M1 enhances central resolution and extends the range of identification from 150 to 200 meters on highways, so that the vehicle can detect distant road conditions earlier. On city roads, M1 increases the frame rate from 10Hz to 20Hz and scans obstacles – such as pedestrians, electric bicycles and traffic jams – at a higher frequency for stronger near-field detection.
A multi-sensor, LiDAR-centric solution is key for accuracy and detection safety, whose reliability is known as the first step towards safe smart mobility. As Chinese LiDAR companies continue making breakthroughs in the global march towards smart mobility, RoboSense has become a leader in China and will continue in its commitment to innovate and supply the global intelligent automotive value chain with LiDAR solutions, accelerating the evolution of smart mobility.
About Yole Développement ( www.yole.fr ）
Yole Développement provides market research, technology analysis, strategy consulting, targeted media, and financial advisory services. With a strong focus on emerging applications using silicon and/or micro manufacturing since 1998, Yole Développement has expanded to include more than 80 collaborators worldwide.
About RoboSense (www.robosense.ai):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005530/en/
Contact information
Grace Ye
RoboSense PR Manager
grace.ye@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom